Historique
Périodique
Cost-effectiveness of harm reduction in preventing Hepatitis C among injection drug users
(Coût-efficacité des programmes de réduction des risques concernant l'hépatite C chez les injecteurs de drogue.)
Auteur(s) :
POLLACK, H. A.
Année
2001
Page(s) :
357-367
Langue(s) :
Anglais
Refs biblio. :
58
Domaine :
Drogues illicites / Illicit drugs
Discipline :
MAL (Maladies infectieuses / Infectious diseases)
Thésaurus mots-clés
REDUCTION DES RISQUES ET DES DOMMAGES
;
ECHANGE DE SERINGUES
;
EFFICACITE
;
HEPATITE
;
CONTAMINATION
;
ETUDE PROSPECTIVE
Note générale :
Medical Decision Making, 2001, (sept.-oct.), 357-367
Note de contenu :
fig.
Résumé :
ENGLISH :
Objectives. Hepatitis C (HCV) has emerged as a major epidemic among injection drug users (IDUs), with observed prevalence exceeding 70% in many American and European cities. This article explores the potential of syringe exchange programs (SEPs) to reduce HCV incidence and prevalence. Design. A random-mixing epidemiological model is used to examine the potential impact of harm reduction interventions. Methods. Steady-state analysis is used to scrutinize the impact of SEP on HCV incidence and prevalence and to examine the accuracy of short-term incidence analysis in predicting long-run program effects. Results. SEP is predicted to have little impact on HCV incidence and prevalence within realistic populations of IDUs. Conclusions. Short-term incidence analysis substantially overstates SEP effectiveness and cost-effectiveness in preventing HCV. More comprehensive harm reduction models, coupled with referral of active IDUs to treatment, must complement syringe exchange to successfully contain highly infectious blood-borne diseases. (Editor' s abstract)
Affiliation :
Dep. Health Management and Policy, Univ. Michigan Sch. Public Hlth, 109 S. Observatory, Ann Arbor, MI 48109-2029
France. France.
France. France.